(lp0
S'OXiGENE Announces Name Change to Mateon Therapeutics GlobeNewswire  - Jun 17, 2016 SOUTH SAN FRANCISCO, Calif., June 17, 2016  -- OXiGENE, Inc. , a biopharmaceutical company developing vascular disrupting agents  for orphan oncology indications, today announced that it has changed its&nbsp;...'
p1
aS'Mateon Therapeutics to Present at 29th Annual ROTH Conference GlobeNewswire  - Mar 8, 2017 SOUTH SAN FRANCISCO, Calif., March 08, 2017  -- Mateon Therapeutics, Inc. , a biopharmaceutical company developing vascular disrupting agents  for the treatment of orphan oncology indications, today&nbsp;...'
p2
aS'Mateon Therapeutics Announces Initial Pre-clinical Data on Combination of CA4P ... GlobeNewswire  - Feb 13, 2017 SOUTH SAN FRANCISCO, Calif., Feb. 13, 2017  -- Mateon Therapeutics, Inc. , a biopharmaceutical company developing vascular disrupting agents  for the treatment of orphan oncology indications, today&nbsp;...'
p3
aS'MATEON THERAPEUTICS, INC.  Files An 8-K Other Events Market Exclusive - Mar 15, 2017 Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents  for the treatment of cancer.Mateon Therapeutics Announces Initial Data from Third Cohort of Phase 1b Study ... - GlobeNewswire Mateon Therapeutics Inc  Rating Reiterated by Rodman &amp; Renshaw - BNB Daily '
p4
aS'UPDATE -- Mateon Therapeutics to Present New Improved Survival Outcomes for ... GlobeNewswire  - Jun 20, 2016 SOUTH SAN FRANCISCO, Calif., June 20, 2016  -- Mateon Therapeutics, Inc. , formerly OXiGENE, Inc. , a biopharmaceutical company developing vascular disrupting agents  for the treatment of&nbsp;...'
p5
aS"Mateon Therapeutics Inc  to Release Quarterly Earnings on Monday Chaffey Breeze - Mar 25, 2017 Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics Inc and related companies with MarketBeat.com's FREE daily ratings newsletter."
p6
aS'OTC Markets Group Welcomes Mateon Therapeutics to OTCQX PR Newswire  - Dec 8, 2016 8, 2016 /PRNewswire/ -- OTC Markets Group Inc. , operator of financial markets for 10,000 U.S. and global securities, today announced Mateon Therapeutics, Inc. , a biopharmaceutical company developing vascular disrupting&nbsp;...'
p7
aS'Is The Mateon Therapeutics Inc  Delisting A Discount Op? Market Exclusive - Nov 25, 2016 Mateon Therapeutics Inc  has spent the last few months petitioning its shareholders for approval of a reverse split.'
p8
aS"OXiGENE: A Frustrating Company That Remains Cheap Seeking Alpha - Oct 6, 2015 From reviewing my belief OXiGENE was a speculative buy last November, I did not sufficiently consider the lengthy time to get FDA feedback and the company's history of futility. While the clinical update this past week seemed generally positive given ..."
p9
aS'Mateon Announces Initiation of FOCUS Study in Platinum-Resistant Ovarian Cancer GlobeNewswire  - Jun 23, 2016 SOUTH SAN FRANCISCO, Calif., June 23, 2016  -- Mateon Therapeutics, Inc. , a biopharmaceutical company developing vascular disrupting agents  for the treatment of orphan oncology indications, today&nbsp;...'
p10
a.